search
Back to results

Human Chorionic Gonadotropin Supplementation Prior to In-vitro Fertilization Treatment in Poor Responders

Primary Purpose

Infertility

Status
Unknown status
Phase
Not Applicable
Locations
Israel
Study Type
Interventional
Intervention
Ovitrelle
Sponsored by
Hadassah Medical Organization
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Infertility focused on measuring in-vitro fertilization, poor responders, human chorionic gonadotropin, Fertility Agents, Female

Eligibility Criteria

40 Years - 45 Years (Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • women >39 years on IVF treatment

Exclusion Criteria:

  • polycystic ovary syndrome
  • Any allergy to injection of human chorionic gonadotropin before

Sites / Locations

  • Hadassah Medical Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

No Intervention

Arm Label

Ovitrelle supplemantation

no Ovitrelle supplementation

Arm Description

The women will be given 250 mcg of Ovitrelle prior to their IVF cycle

Outcomes

Primary Outcome Measures

number of oocytes retrieved

Secondary Outcome Measures

Full Information

First Posted
August 30, 2010
Last Updated
March 1, 2011
Sponsor
Hadassah Medical Organization
search

1. Study Identification

Unique Protocol Identification Number
NCT01205009
Brief Title
Human Chorionic Gonadotropin Supplementation Prior to In-vitro Fertilization Treatment in Poor Responders
Study Type
Interventional

2. Study Status

Record Verification Date
September 2010
Overall Recruitment Status
Unknown status
Study Start Date
April 2011 (undefined)
Primary Completion Date
March 2012 (Anticipated)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
Hadassah Medical Organization

4. Oversight

5. Study Description

Brief Summary
In an era of delayed fertility plans, there is increasing need for fertility treatment in older women with poor response. Human chorionic gonadotropin (hCG) supplementation prior to treatment, as a thecal stimulant, may improve folliculogenesis and ovarian response.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Infertility
Keywords
in-vitro fertilization, poor responders, human chorionic gonadotropin, Fertility Agents, Female

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
100 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Ovitrelle supplemantation
Arm Type
Active Comparator
Arm Description
The women will be given 250 mcg of Ovitrelle prior to their IVF cycle
Arm Title
no Ovitrelle supplementation
Arm Type
No Intervention
Intervention Type
Drug
Intervention Name(s)
Ovitrelle
Intervention Description
One dose of Ovitrelle 250 mcg
Primary Outcome Measure Information:
Title
number of oocytes retrieved
Time Frame
1 month

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
40 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: women >39 years on IVF treatment Exclusion Criteria: polycystic ovary syndrome Any allergy to injection of human chorionic gonadotropin before
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Mushira Aboo Dia,, MD
Email
mushiraa@gmail.com
First Name & Middle Initial & Last Name or Official Title & Degree
Hadas Lemberg, PhD
Phone
00 972 2 6777572
Email
lhadas@hadassah.org.il
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mushira Aboo Dia, MD
Organizational Affiliation
Hadassah Medical Organization
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hadassah Medical Center
City
Jerusalem
Country
Israel
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Arik Tzukert, DMD
Phone
0097226776095
Email
arik@hadassah.org.il
First Name & Middle Initial & Last Name & Degree
Mushira Aboo Dia, MD
Phone
0097226776425
Email
mushiraa@gmail.com

12. IPD Sharing Statement

Learn more about this trial

Human Chorionic Gonadotropin Supplementation Prior to In-vitro Fertilization Treatment in Poor Responders

We'll reach out to this number within 24 hrs